Insider Selling: Robert Roswell Chai-Onn Sells 10,203 Shares of Valeant Pharmaceuticals Intl Stock (VRX)
Valeant Pharmaceuticals Intl (NYSE:VRX) EVP Robert Roswell Chai-Onn sold 10,203 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $121.70, for a total transaction of $1,241,705.10. Following the transaction, the executive vice president now directly owns 23,999 shares in the company, valued at approximately $2,920,678. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded down 0.57% during mid-day trading on Tuesday, hitting $120.52. 2,201,761 shares of the company’s stock traded hands. Valeant Pharmaceuticals Intl has a 52 week low of $83.45 and a 52 week high of $153.10. The stock’s 50-day moving average is $127.3 and its 200-day moving average is $129.. The company’s market cap is $40.406 billion. Valeant Pharmaceuticals Intl also was the target of unusually large options trading activity on Monday. Stock investors bought 8,293 call options on the company. This represents an increase of 150% compared to the typical daily volume of 3,323 call options.
Valeant Pharmaceuticals Intl (NYSE:VRX) last posted its quarterly earnings results on Thursday, May 8th. The company reported $1.76 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.72 by $0.04. The company had revenue of $1.85 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the company posted $1.30 earnings per share. Valeant Pharmaceuticals Intl’s revenue was up 76.6% compared to the same quarter last year. Analysts expect that Valeant Pharmaceuticals Intl will post $8.73 EPS for the current fiscal year.
A number of research firms have recently commented on VRX. Analysts at Cantor Fitzgerald raised their price target on shares of Valeant Pharmaceuticals Intl to $209.00 in a research note on Monday, June 2nd. Separately, analysts at CIBC initiated coverage on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, May 21st. They set an “outperform” rating and a $160.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research note on Friday, May 16th. They now have a $153.00 price target on the stock. One research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $150.90.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.